Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

 

Search in our Online Store

Antibodies
Filter     Order     Display # 
Date Item Title
19 Sep 2007 Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and Immunology
14 Sep 2007 Genmab Discloses Target and Development Plans for HuMax-Inflam
14 Sep 2007 Genmab Provides Insights into IgG4 Antibodies
13 Sep 2007 DAHANCA Initiates Head and Neck Cancer Study with Genmab's HuMax-EGFr
13 Sep 2007 XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
12 Sep 2007 Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485
11 Sep 2007 Merck: Erbitux Phase III Study - FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer
11 Sep 2007 Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
08 Sep 2007 Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeutics
08 Sep 2007 ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
08 Sep 2007 Genmab announces encouraging preclinical data for Ofatumumab
06 Sep 2007 Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
06 Sep 2007 Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
06 Sep 2007 Access and Somanta Announce New Data on Angiolix(R) Humanized Monoclonal Antibody
05 Sep 2007 YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiation
05 Sep 2007 Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
04 Sep 2007 Merck Applies to Extend Use of Erbitux(R) for 1st-Line Colorectal Cancer
31 Aug 2007 YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
30 Aug 2007 Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients
29 Aug 2007 Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment
29 Aug 2007 Baxter and the Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer's Disease
29 Aug 2007 XOMA Licenses Antibody Technology to Pfizer
25 Aug 2007 Phase II study of IMC-1121B for advanced renal cell cancer opens for patient enrollment
25 Aug 2007 Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
25 Aug 2007 Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with Paclitaxel for first-line metastatic breast cancer
24 Aug 2007 Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated
23 Aug 2007 MedImmune's motavizumab reduced RSV hospitalizations by 83 percent among high-risk native American, full-term infants in placebo-controlled Phase 3 study
22 Aug 2007 YM BioSciences', European partner, Oncoscience AG, announces initiation of advanced nimotuzumab trials in adult glioma and pancreatic cancer
22 Aug 2007 Protox acquires research program from Medicenna
21 Aug 2007 Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
21 Aug 2007 PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
17 Aug 2007 Auxilium Pharmaceuticals, Inc. receives clearance to resume clinical trials for XIAFLEX(TM)
16 Aug 2007 Anadis to use its polyclonal antibodies for treatment
16 Aug 2007 Cell Therapeutics, Inc. (CTI) enters agreement to acquire lymphoma drug Zevalin(R) from Biogen Idec for sales and marketing in the United States
15 Aug 2007 Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab
10 Aug 2007 Roche files IND for second Genmab antibody
10 Aug 2007 Rilonacept (IL-1 Trap) granted FDA priority review for the treatment of CAPS
09 Aug 2007 ORENCIA(R) (abatacept) supplemental biologics license application for juvenile idiopathic arthritis accepted by FDA for filing and review
09 Aug 2007 InNexus Biotechnology unveils new platform for augmenting antibody therapeutics
08 Aug 2007 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Enter into Agreement to Humanize Two Monoclonal Antibodies for the Treatment of Alzheimer's Disease
04 Aug 2007 Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD)
03 Aug 2007 Genmab regains rights to HuMax-TAC
03 Aug 2007 Macrogenics Begins Global Phase 2/3 Protege Study In Recent-onset Type 1 Diabetes Mellitus
02 Aug 2007 ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4
02 Aug 2007 Phase 2a Multi-dose Study Initiated By Medimmune In Patients With Asthma To Further Expand Anti-interleukin-9 Program
01 Aug 2007 ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
01 Aug 2007 Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim(TM)
01 Aug 2007 YM BioSciences initiates patient enrolment in phase II colorectal cancer trial with EGFR antibody
01 Aug 2007 Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
31 Jul 2007 BioWa Introduces its Second Technology to Dramatically Enhance Antibody Effector Function and the Launch of AccretaMab(TM) Platform
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 401 - 450 of 1053

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics